MALAKOFF, France--(BUSINESS WIRE)--Regulatory News:
THERACLION (Paris:ALTHE) (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, announces today the advanced discussions with 2 key opinion leaders as well as business partners organized within the frame of David Caumartin’s (CEO Theraclion) participation in the visit of French President François Hollande to South Korea. The French President visited South Korea November 4, 2015 at the invitation of Korean President Park Geun-hye. This trip was intended to give new impetus to the global partnership between France and Korea in the political, economic, academic, scientific and cultural sectors.
On this occasion several French companies were selected to accompany the President so to meet the Korean market and potential business partners. Theraclion, having recently concluded a commercial agreement with Korea, was among those chosen to participate in the presidential delegation and was introduced to Korean interlocutors as a symbol of the innovative French Medtech. During the visit, the French and Korean presidents applauded the excellent bilateral relations in the field of technological innovation, perfectly illustrated by the close partnership between Theraclion and Echo Healthcare Inc..
"Today, we visited 2 key opinion leaders, Dr Paik of the EHWA Women Health Center and Dr Yoon of Gagnam St. Peter’s." said Mr. Kim, CEO, Echo Healthcare Inc. “Both doctors were particularly impressed with the non-invasive nature of the Echopulse treatment after having seen a demonstration of the procedure on a phantom.”
“This visit was a great opportunity to strengthen our commercial footprint in Korea, a key market in Asia,” adds David Caumartin, CEO THERACLION. "The momentum created will help us accelerate our growth in Korea, a country in which pathologies of the thyroid are numerous and treated in very innovative ways by the medical profession."
About Theraclion
Theraclion is a French company specializing in high-tech medical
equipment using therapeutic ultrasound. Drawing on leading-edge
technologies, Theraclion has designed and manufactured an innovative
solution for echotherapy, the Echopulse®, allowing non-invasive tumor
treatment through ultrasound-guided high-intensity focused ultrasound.
Theraclion
is ISO 13485 certified and has received the CE mark for non-invasive
ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff,
near Paris, France Theraclion has brought together a team of 30 people,
53 percent of whom are dedicated to R&D and clinical trials. For more
information, please visit Theraclion’s website: www.theraclion.com.
Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic:
ALTHE - ISIN Code: FR0010120402